HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Analysts focus on three programs in big year for Bristol Myers

Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a dozen trial results expected by the end of 2026, in ...

By Endpoints News · Apr 30, 2026 · via Endpoints News
Analysts focus on three programs in big year for Bristol Myers

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News →

Tags
moneyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
MoneyFiercePharma ↗
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugm…
May 1, 2026
MoneyDrug Channels ↗
Where Gross-to-net Pressure Actually Lives After Launch
Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx. Cindy explains that many gro…
May 1, 2026
Avalyn’s $300M IPO Signals Renewed Appetite for Reformulation Plays
MoneyBriefing
Avalyn’s $300M IPO Signals Renewed Appetite for Reformulation Plays
Avalyn Pharma priced its Nasdaq debut at the top of range, raising $300M to push inhaled versions of existing …
Apr 30, 2026